Yesterday in Orlando Judges heard argument regarding an MDL for Ortho Evra. Johnson and Johnson appears to agree to an MDL, but the location may be the issue. Several Plaintiffs' attorneys asked that the MDL be sent to New Jersey.
The FDA on November 10, 2005 informed the public that an updated new label for the patch was to include information its use of higher levels of estrogen.
Females who use Ortho Evra are exposed to 60 percent more estrogen than those who use the pill, according to the FDA.
The FDA received 21 reports of blood clots and other serious injury allegedly linked to use of the patch. The patch has been linked to the deaths of at least seventeen young American women over the past two years.
